EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Multi-Gene Next-Generation Sequencing Panel for Analysis of BRCA1/BRCA2 and Homologous Recombination Repair Genes Alterations Metastatic Castration-Resistant Prostate Cancer

Thais Maloberti iD, Antonio De Leo iD, Sara Coluccelli iD, Viviana Sanza, Elisa Gruppioni iD, Annalisa Altimari, Stefano Zagnoni, Francesca Giunchi, Francesco Vasuri, Michelangelo Fiorentino iD, Veronica Mollica iD, Simona Ferrari und 6 weitere

International Journal of Molecular Sciences · 2023

DOI: 10.3390/ijms24108940 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Thais Maloberti und 17 weiteren Autor:innen. Beteiligte Einrichtung: Solid Tumor Molecular Pathology Laboratory, IRCCS Azienda Ospedaliero-Universitaria di Bologna, 40138 Bologna, Italy. Hauptthemen laut MEDLINE: Genes, BRCA2, Prostatic Neoplasms, Castration-Resistant. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministero della Salute, Italian Ministry of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Despite significant therapeutic advances, metastatic CRPC (mCRPC) remains a lethal disease. Mutations in homologous recombination repair (HRR) genes are frequent in mCRPC, and tumors harboring these mutations are known to be sensitive to PARP inhibitors. The aim of this study was to verify the technical effectiveness of this panel in the analysis of mCRPC, the frequency and type of mutations in the BRCA1/BRCA2 genes, as well as in the homologous recombination repair (HRR) genes. A total of 50 mCRPC cases were analyzed using a multi-gene next-generation sequencing panel evaluating a total of 1360 amplicons in 24 HRR genes. Of the 50 cases, 23 specimens (46.0%) had an mCRPC harboring a pathogenic variant or a variant of uncertain significance (VUS), whereas in 27 mCRPCs (54.0%), no mutations were detected (wild-type tumors). BRCA2 was the most commonly mutated gene (14.0% of samples), followed by ATM (12.0%), and BRCA1 (6.0%). In conclusion, we have set up an NGS multi-gene panel that is capable of analyzing BRCA1/BRCA2 and HRR alterations in mCRPC. Moreover, our clinical algorithm is currently being used in clinical practice for the management of patients with mCRPC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Genes, BRCA2Prostatic Neoplasms, Castration-ResistantMaleHumansRecombinational DNA RepairGerm-Line MutationBiomarkers, TumorHigh-Throughput Nucleotide SequencingBRCA1 ProteinBRCA2 Protein

Stichwörter der Autor:innen

BRCA1BRCA2HRRmCRPCmutationsnext-generation sequencingprostatic adenocarcinoma

Substanzen

Biomarkers, TumorBRCA1 protein, humanBRCA1 ProteinBRCA2 protein, humanBRCA2 Protein

Autor:innen und Institutionen

  • Solid Tumor Molecular Pathology Laboratory, IRCCS Azienda Ospedaliero-Universitaria di Bologna, 40138 Bologna, Italy.
  • Department of Medical and Surgical Sciences (DIMEC), University of Bologna, 40138 Bologna, Italy.
  • Pathology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, 40138 Bologna, Italy.
  • Pathology Unit, Maggiore Hospital, AUSL Bologna, 40133 Bologna, Italy.
  • Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, 40138 Bologna, Italy.
  • Unit of Medical Genetics, IRCCS Azienda Ospedaliero-Universitaria di Bologna, 40138 Bologna, Italy.

ORCID-Profile: Thais Maloberti, Antonio De Leo, Sara Coluccelli, Elisa Gruppioni, Michelangelo Fiorentino, Veronica Mollica, Sara Miccoli, Michela Visani, Francesco Massari, Dario de Biase

Förderung

  • Ministero della Salute
  • Italian Ministry of Health

Zitieren

APA

Maloberti, T., De Leo, A., Coluccelli, S., Sanza, V., Gruppioni, E., Altimari, A., Zagnoni, S., Giunchi, F., Vasuri, F., Fiorentino, M., Mollica, V., Ferrari, S., Miccoli, S., Visani, M., Turchetti, D., Massari, F., Tallini, G., & de Biase, D. (2023). Multi-Gene Next-Generation Sequencing Panel for Analysis of BRCA1/BRCA2 and Homologous Recombination Repair Genes Alterations Metastatic Castration-Resistant Prostate Cancer. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms24108940

Vancouver

Maloberti T, De Leo A, Coluccelli S, Sanza V, Gruppioni E, Altimari A, et al. Multi-Gene Next-Generation Sequencing Panel for Analysis of BRCA1/BRCA2 and Homologous Recombination Repair Genes Alterations Metastatic Castration-Resistant Prostate Cancer. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms24108940

BibTeX
@article{Maloberti2023,
  author = {Maloberti, Thais and De Leo, Antonio and Coluccelli, Sara and Sanza, Viviana and Gruppioni, Elisa and Altimari, Annalisa and Zagnoni, Stefano and Giunchi, Francesca and Vasuri, Francesco and Fiorentino, Michelangelo and Mollica, Veronica and Ferrari, Simona and Miccoli, Sara and Visani, Michela and Turchetti, Daniela and Massari, Francesco and Tallini, Giovanni and de Biase, Dario},
  title = {Multi-Gene Next-Generation Sequencing Panel for Analysis of BRCA1/BRCA2 and Homologous Recombination Repair Genes Alterations Metastatic Castration-Resistant Prostate Cancer},
  journal = {International Journal of Molecular Sciences},
  year = {2023},
  doi = {10.3390/ijms24108940}
}
Kostenlos starten →